ViroGates A/S

Copenhagen Stock Exchange VIRO.CO

ViroGates A/S Gross Profit Margin for the year ending December 31, 2023: 83.08%

ViroGates A/S Gross Profit Margin is 83.08% for the year ending December 31, 2023, a -0.24% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

ViroGates A/S Gross Profit Margin for the year ending December 31, 2022 was 83.28%, a 10.16% change year over year.
ViroGates A/S Gross Profit Margin for the year ending December 31, 2021 was 75.60%, a -3.40% change year over year.
ViroGates A/S Gross Profit Margin for the year ending December 31, 2020 was 78.26%, a -12.34% change year over year.
ViroGates A/S Gross Profit Margin for the year ending December 31, 2019 was 89.28%, a -1.45% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Copenhagen Stock Exchange: VIRO.CO

ViroGates A/S

CEO	Mr. Jakob Knudsen
IPO Date	June 26, 2018
Location	Denmark
Headquarters	BanevAenget 13
Employees	10
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Medical Instruments

Description

ViroGates A/S develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging; and suPARnostic ELISA that provides fully quantitative results. Its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was incorporated in 2000 and is headquartered in Birkerød, Denmark.

Key trends

Past 5 years